PubRank

CD70: An emerging target in cancer immunotherapy.

PubWeight™: 0.81‹?›

🔗 View Article (PMID 26213107)

Published in Pharmacol Ther on July 26, 2015

Authors

J Jacobs1, V Deschoolmeester2, K Zwaenepoel3, C Rolfo4, K Silence5, S Rottey6, F Lardon7, E Smits8, P Pauwels2

Author Affiliations

1: Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Department of Pathology, Antwerp University Hospital, Edegem, Belgium. Electronic address: julie.jacobs@uantwerpen.be.
2: Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
3: Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
4: Department of Oncology, Antwerp University Hospital, Edegem, Belgium; Phase 1-Early Clinical Trials Unit, Antwerp University Hospital, Edegem, Belgium.
5: arGEN-X BVBA, Ghent, Belgium.
6: Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium.
7: Center for Oncological Research, University of Antwerp, Wilrijk, Belgium.
8: Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Laboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute, University of Antwerp, Edegem, Belgium.

Articles citing this ↘

Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency. J Exp Med (2016) 0.78

Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res (2015) 0.78

Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection. J Exp Med (2016) 0.77

NUDT2 Disruption Elevates Diadenosine Tetraphosphate (Ap4A) and Down-Regulates Immune Response and Cancer Promotion Genes. PLoS One (2016) 0.76

Pre-clinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. Clin Cancer Res (2016) 0.75

Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma. Oncotarget (2017) 0.75